Geoepidemiology and changing mortality in primary biliary cholangitis

Annarosa Floreani, Atsushi Tanaka, Christopher Bowlus, M. Eric Gershwin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Primary biliary cholangitis (PBC), formerly called primary biliary cirrhosis, is a chronic cholestatic disease characterized by an autoimmune-mediated destruction of small and medium-sized intrahepatic bile ducts. Originally PBC was considered to be rare and almost invariably fatal, mainly because the diagnosis was made in patients presenting with advanced symptomatic disease (jaundice and decompensated cirrhosis). However, the development of a reproducible indirect immunofluorescence assay for antimitochondrial antibody made it possible to diagnose the disease at an earlier stage, and introduction of ursodeoxycholic acid therapy as the first-line therapy for PBC drastically changed PBC-related mortality. At present, patients with an early histological stage have survival rates similar to those of an age- and sex-matched control population. Although 30% of patients treated with ursodeoxycholic acid may exhibit incomplete responses, obeticholic acid and drugs currently in development are expected to be effective for these patients and improve outcomes. Meanwhile, more etiology and immunopathology studies using new technologies and novel animal models are needed to dissect variances of clinical course, treatment response, and outcome in each patient with PBC. Precision medicine that is individualized for each patient on the basis of the cause identified is eagerly awaited.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalJournal of Gastroenterology
DOIs
StateAccepted/In press - Apr 1 2017

Fingerprint

Cholangitis
Mortality
Ursodeoxycholic Acid
Intrahepatic Bile Ducts
Precision Medicine
Biliary Liver Cirrhosis
Indirect Fluorescent Antibody Technique
Jaundice
Fibrosis
Chronic Disease
Survival Rate
Animal Models
Technology
Antibodies
Therapeutics
Pharmaceutical Preparations
Population

Keywords

  • Cirrhosis
  • Etiology
  • Obeticholic acid
  • Precision medicine
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Geoepidemiology and changing mortality in primary biliary cholangitis. / Floreani, Annarosa; Tanaka, Atsushi; Bowlus, Christopher; Gershwin, M. Eric.

In: Journal of Gastroenterology, 01.04.2017, p. 1-8.

Research output: Contribution to journalArticle

@article{f0997d828c63434dac9cf06fa19830ce,
title = "Geoepidemiology and changing mortality in primary biliary cholangitis",
abstract = "Primary biliary cholangitis (PBC), formerly called primary biliary cirrhosis, is a chronic cholestatic disease characterized by an autoimmune-mediated destruction of small and medium-sized intrahepatic bile ducts. Originally PBC was considered to be rare and almost invariably fatal, mainly because the diagnosis was made in patients presenting with advanced symptomatic disease (jaundice and decompensated cirrhosis). However, the development of a reproducible indirect immunofluorescence assay for antimitochondrial antibody made it possible to diagnose the disease at an earlier stage, and introduction of ursodeoxycholic acid therapy as the first-line therapy for PBC drastically changed PBC-related mortality. At present, patients with an early histological stage have survival rates similar to those of an age- and sex-matched control population. Although 30{\%} of patients treated with ursodeoxycholic acid may exhibit incomplete responses, obeticholic acid and drugs currently in development are expected to be effective for these patients and improve outcomes. Meanwhile, more etiology and immunopathology studies using new technologies and novel animal models are needed to dissect variances of clinical course, treatment response, and outcome in each patient with PBC. Precision medicine that is individualized for each patient on the basis of the cause identified is eagerly awaited.",
keywords = "Cirrhosis, Etiology, Obeticholic acid, Precision medicine, Ursodeoxycholic acid",
author = "Annarosa Floreani and Atsushi Tanaka and Christopher Bowlus and Gershwin, {M. Eric}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s00535-017-1333-2",
language = "English (US)",
pages = "1--8",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Geoepidemiology and changing mortality in primary biliary cholangitis

AU - Floreani, Annarosa

AU - Tanaka, Atsushi

AU - Bowlus, Christopher

AU - Gershwin, M. Eric

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Primary biliary cholangitis (PBC), formerly called primary biliary cirrhosis, is a chronic cholestatic disease characterized by an autoimmune-mediated destruction of small and medium-sized intrahepatic bile ducts. Originally PBC was considered to be rare and almost invariably fatal, mainly because the diagnosis was made in patients presenting with advanced symptomatic disease (jaundice and decompensated cirrhosis). However, the development of a reproducible indirect immunofluorescence assay for antimitochondrial antibody made it possible to diagnose the disease at an earlier stage, and introduction of ursodeoxycholic acid therapy as the first-line therapy for PBC drastically changed PBC-related mortality. At present, patients with an early histological stage have survival rates similar to those of an age- and sex-matched control population. Although 30% of patients treated with ursodeoxycholic acid may exhibit incomplete responses, obeticholic acid and drugs currently in development are expected to be effective for these patients and improve outcomes. Meanwhile, more etiology and immunopathology studies using new technologies and novel animal models are needed to dissect variances of clinical course, treatment response, and outcome in each patient with PBC. Precision medicine that is individualized for each patient on the basis of the cause identified is eagerly awaited.

AB - Primary biliary cholangitis (PBC), formerly called primary biliary cirrhosis, is a chronic cholestatic disease characterized by an autoimmune-mediated destruction of small and medium-sized intrahepatic bile ducts. Originally PBC was considered to be rare and almost invariably fatal, mainly because the diagnosis was made in patients presenting with advanced symptomatic disease (jaundice and decompensated cirrhosis). However, the development of a reproducible indirect immunofluorescence assay for antimitochondrial antibody made it possible to diagnose the disease at an earlier stage, and introduction of ursodeoxycholic acid therapy as the first-line therapy for PBC drastically changed PBC-related mortality. At present, patients with an early histological stage have survival rates similar to those of an age- and sex-matched control population. Although 30% of patients treated with ursodeoxycholic acid may exhibit incomplete responses, obeticholic acid and drugs currently in development are expected to be effective for these patients and improve outcomes. Meanwhile, more etiology and immunopathology studies using new technologies and novel animal models are needed to dissect variances of clinical course, treatment response, and outcome in each patient with PBC. Precision medicine that is individualized for each patient on the basis of the cause identified is eagerly awaited.

KW - Cirrhosis

KW - Etiology

KW - Obeticholic acid

KW - Precision medicine

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=85016451566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016451566&partnerID=8YFLogxK

U2 - 10.1007/s00535-017-1333-2

DO - 10.1007/s00535-017-1333-2

M3 - Article

C2 - 28365879

AN - SCOPUS:85016451566

SP - 1

EP - 8

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

ER -